PROgastrine COlon DEpistage

ECS-Progastrin SA260 enrolled

Overview

Dosage of progastrin in asymptomatic person participating in colon cancer screening

For anyone who will participate in colon screening at the Princess Grace Hospital of Monaco and who has signed the informed consent document. A blood test will be performed in addition to the screening test to assess the rate of progastrin.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

260

Conditions

Colon Cancer Screening Healthy Person

Interventions

progastrinDIAGNOSTIC_TEST

PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.

Eligibility

Sex: ALLMin age: 50 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * participant in colon cancer screening * signing informed consent Exclusion Criteria: * any major medical, psychiatric or addictive illness that would affect the informed consent process * The consent of a representative is not allowed in this study

Locations (1)

Centre Hospitalier Princesse Grace, Monaco

Montpellier, MC, France

Outcomes

Primary Outcomes

progastrin rate

measuring the rate of progastrin in the blood

Time frame: from 15 days to 2 months (until results are obtained)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.